T. E. Witzig
Impact in
- Toxicology top 2%
- Bioactive Compounds and Antitumor Agents
- Oncology top 10%
- Inflammatory Biomarkers in Disease Prognosis
Papers in ⓘ
- Genetics 4
- Chronic Lymphocytic Leukemia Research 4
-
- Lymphoma Diagnosis and Treatment 6
- Co-authors
- Alex A. Adjei (1 shared paper)Irene M. Ghobrial (1 shared paper)Thomas M. Habermann (2 shared papers)David J. Inwards (1 shared paper)Ivana N. Micallef (1 shared paper)Joseph P. Colgan (1 shared paper)Luis F. Porrata (1 shared paper)Steven M. Ansell (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)CA A Cancer Journal for Clinicians (1 paper)Cancer (1 paper)HemaSphere (1 paper)European Journal Of Haematology (1 paper)
- Partner nations
- United StatesAustraliaItaly
In The Last Decade
T. E. Witzig
12 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 105
- Toxicology 85
- Oncology 427
- Cancer Research 193
- Molecular Biology 879
- Pathology and Forensic Medicine 213
Countries citing papers authored by T. E. Witzig
This map shows the geographic impact of T. E. Witzig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. E. Witzig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. E. Witzig more than expected).
Fields of papers citing papers by T. E. Witzig
This network shows the impact of papers produced by T. E. Witzig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. E. Witzig. The network helps show where T. E. Witzig may publish in the future.
Co-authors
The 25 scholars most cited alongside T. E. Witzig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Targeting Apoptosis Pathways in Cancer Therapy Hit paper breakdown → | 2005 | 1148 |
| 2 | 2011 | 162 | |
| 3 | 2009 | 82 | |
| 4 | Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. | 2000 | 43 |
| 5 | 2016 | 35 | |
| 6 | 1991 | 27 | |
| 7 | 1996 | 12 | |
| 8 | 2003 | 12 | |
| 9 | Zevalin radioimmunotherapy is not associated with significant or prolonged depletion of t cells or natural killer cells | 2000 | 3 |
| 10 | 2019 | 1 | |
| 11 | 2004 | 1 | |
| 12 | 2006 | 1 | |
| 13 | 2009 | 1 |
About T. E. Witzig
T. E. Witzig is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Oncology and Nephrology, having authored 13 papers that have together received 1.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (4 papers), Cancer-related Molecular Pathways (2 papers), Lung Cancer Treatments and Mutations (2 papers), Cell death mechanisms and regulation (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Renal Diseases and Glomerulopathies (1 paper). The work is most often cited by research in Toxicology (85 citations), Oncology (427 citations), Cancer Research (193 citations), Molecular Biology (879 citations) and Pathology and Forensic Medicine (213 citations). T. E. Witzig has collaborated with scholars based in United States, Australia and Italy. Frequent co-authors include Alex A. Adjei, Irene M. Ghobrial, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Joseph P. Colgan, Luis F. Porrata, Steven M. Ansell, G. S. Nowakowski and S. N. Markovic. Their work appears in journals such as Journal of Clinical Oncology, CA A Cancer Journal for Clinicians, Cancer, HemaSphere and European Journal Of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.